Vertex Pharmaceuticals Incorporated (VRTX) earnings on August 3, 2026
More Vertex Pharmaceuticals Incorporated earnings
Prior outlook: Pessimistic Outcome: Partial
The stock fell early in the day but turned around and closed 1.7% higher, even climbing as much as 3.6% at its best point.
VRTX price around the earnings
478.71
Change: +1.7%
2026-08-04, 20:00 UTC
Start of the measured window
End of the measured window
462.18
470.69
479.19
487.70
470.72
August 3, 2026
August 4, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Partial
- Thesis published
- Results released
Setup is mixed heading into earnings, but the scenario points pessimistic.
Analysts cite a price target of $557, about 18.3% above the current price, and a 75% beat rate, offset by trajectory collapse and negative trend strength into earnings.
Context analyzed before publication
- Summary
- Setup is mixed heading into earnings, but the scenario points pessimistic.
- Trend
- Collapsed from 54.7 to 0.9; negative trend strength into event creates deteriorating setup.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.66
- Analysts covering the stock
- 24
- Average price target
- 557.13
- Lowest price target
- 350
- Highest price target
- 652
- Upside to price target
- 18.3%
- Quarterly earnings growth
- 59.6%
- Revenue growth
- 7.8%
- Forward EPS
- 21.34
- Trailing EPS
- 16.84
- Analyst moves in the last 60 days
- 4
- Strong buy: 4
- Buy: 19
- Hold: 4
- Sell: 1
- Strong sell: 1
- Strong buy
- 4
- Buy
- 19
- Hold
- 4
- Sell
- 1
- Strong sell
- 1
- July 13, 2026 · UBS: Maintains rating (Buy → Buy)
- July 13, 2026 · Truist Securities: Maintains rating (Buy → Buy)
- July 7, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
- July 7, 2026 · Baird: Maintains rating (Underperform → Underperform)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (8)
- Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday (opens in a new tab) — Benzinga
- AbCellera Announces $28M Upfront Vertex Collaboration On Multispecific T-Cell Engagers For Autoimmune Diseases, Eligible For Milestone Payments And Tiered Royalties (opens in a new tab) — Benzinga
- $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today (opens in a new tab) — Benzinga
- UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585 (opens in a new tab) — Benzinga
- Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560 (opens in a new tab) — Benzinga
- Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’ (opens in a new tab) — Benzinga
- CNBC Halftime Report Final Trades: Nvidia, Vertex Pharmaceuticals, Vanguard Real Estate ETF, Roundhill Memory ETF (opens in a new tab) — Benzinga
- RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $570 (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 477.02
- Average true range (ATR)
- 2.5%
- Distance to 52-week high
- -11.0%
- 14-day change (14d)
- -1.8%
- 30-day change (30d)
- -4.2%
- 30-day relative strength
- +0.9%
- QQQ change (30d)
- -5.2%
- Nearest support
- 474.35
- Distance to nearest support
- 0.6%
- Nearest resistance
- 479.14
- Distance to nearest resistance
- 0.5%
- Volume accumulation ratio (14d / 46d)
- 0.82
- Major: 474.35 (0.6% away, 0.23 ATR, 86 touches)
- Major: 470.2 (1.4% away, 0.58 ATR, 82 touches)
- Major: 467.73 (2% away, 0.79 ATR, 68 touches)
- Major: 479.14 (0.5% away, 0.18 ATR, 71 touches)
- Major: 483.22 (1.3% away, 0.52 ATR, 66 touches)
- Major: 487.47 (2.2% away, 0.88 ATR, 45 touches)
Trends
Evidence
- Average earnings surprise
- +3.2%
- May 4, 2026: actual EPS 4.47 vs estimate 4.31 (surprise +3.8%)
- February 12, 2026: actual EPS 5.03 vs estimate 5.15 (surprise -2.3%)
- November 3, 2025: actual EPS 4.8 vs estimate 4.58 (surprise +4.9%)
- August 4, 2025: actual EPS 4.52 vs estimate 4.25 (surprise +6.3%)
Expected move
- Implied move
- +3.8%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 3.1%
- 75th percentile move
- 5.1%
- 90th percentile move
- 9%
- Up / down moves
- 10 / 10
- Average up move
- +3.6%
- Average down move
- -5.2%
Monitoring and close
What Vertex Pharmaceuticals Incorporated reported
- Status
- Finished
| Actual EPS | 4.73 |
|---|---|
| EPS estimate | 4.75 |
| EPS surprise | -0.3% |
| Revenue | $3,334 million |
| Revenue estimate | $3,223 million |
| Revenue surprise | +3.4% |
Vertex raised its 2026 sales guidance and beat Q2 estimates, but shares fell late Monday following the mixed quarterly report.
Sources (4)
- Vertex Raises 2026 Guidance, But Shares Fall For One Key Reason (opens in a new tab) — Investor's Business Daily
- Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est (opens in a new tab) — Benzinga
- Vertex reported adjusted earnings of $4.73 per share, in line with expectations, and sales of $3.334 billion, beating estimates. — Benzinga
- Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate (opens in a new tab) — Benzinga
Pre-market second reading after the results
- Verdict
- In line with expectations
Heading into the open, results beat expectations on revenue but not on earnings, and the price is indicating -0.8% pre-market, a move below the stock's usual reaction (about 3%). The figures don't confirm the prior scenario: that move is too small to draw conclusions from.
How the stock reacted
- Outcome
- Partial
- Consolidated
- +1.7%
- Max favorable move (MFE)
- 1.7%
- Max adverse move (MAE)
- 3.6%